GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Accounts Payable

Halberd (Halberd) Accounts Payable : $0.58 Mil (As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Accounts Payable?

Halberd's Accounts Payable for the quarter that ended in Jul. 2023 was $0.58 Mil.

Halberd's quarterly Accounts Payable increased from Jul. 2008 ($0.02 Mil) to Jul. 2022 ($0.38 Mil) and increased from Jul. 2022 ($0.38 Mil) to Jul. 2023 ($0.58 Mil).

Halberd's annual Accounts Payable increased from Jul. 2008 ($0.02 Mil) to Jul. 2022 ($0.38 Mil) and increased from Jul. 2022 ($0.38 Mil) to Jul. 2023 ($0.58 Mil).


Halberd Accounts Payable Historical Data

The historical data trend for Halberd's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Accounts Payable Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Accounts Payable
0.02 0.38 0.58

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Accounts Payable 0.02 0.38 0.58

Halberd Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Halberd Accounts Payable Related Terms

Thank you for viewing the detailed overview of Halberd's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Halberd (Halberd) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236